PremiumRatingsBiodesix: Strong Growth and Promising Future with Buy Rating from Kyle Mikson CFA Biodesix: Promising Financial Outlook and Strategic Execution Justify Buy Rating Biodesix Reports Strong 2024 Financial Performance PremiumThe FlyBiodesix announces publication of new Nodify CDT clinical validation study Biodesix Reports Strong Q3 2024 Growth in Diagnostics Morning Movers: Apple dips, Amazon gains after earnings PremiumCompany AnnouncementsBiodesix Releases Updated Corporate Presentation Information Biodesix raises FY24 revenue view to $70M-$72M from $65M-$68M Biodesix reports Q2 EPS (8c), consensus (9c) 
